|
1
|
Travis WD, Brambilla E, Muller-Hermelink
HD and Harris CC: World Health Organization classification of
tumors. Pathology and Genetics of Tumors of the Lung, Pleura,
Thymus and Hearth. IARC Press; Lyon: 2004
|
|
2
|
Righi L, Volante M, Rapa I, Scagliotti GV
and Papotti M: Neuro-endocrine tumours of the lung. A review of
relevant pathological and molecular data. Virchows Arch.
451:S51–S59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gustafsson BI, Kidd M, Chan A,
Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine
tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cooper WA, Thourani VH, Gal AA, Lee RB,
Mansour KA and Miller JI: The surgical spectrum of pulmonary
neuroendocrine neoplasms. Chest. 119:14–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asamura H, Kameya T, Matsuno Y, Noguchi M,
Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima
K and Nagai K: Neuroendocrine neoplasms of the lung: a prognostic
spectrum. J Clin Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
García-Yuste M, Matilla JM and
González-Aragoneses F: Neuroendocrine tumors of the lung. Curr Opin
Oncol. 20:148–154. 2008.
|
|
7
|
Srirajaskanthan R, Toumpanakis C,
Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T and Caplin
ME: Surgical management and palliative treatment in bronchial
neuroendocrine tumours: a clinical study of 45 patients. Lung
Cancer. 65:68–73. 2009. View Article : Google Scholar
|
|
8
|
Katso R, Okkenhaug K, Ahamdi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vivanco I and Sawyers CL: The
phosphatidylinositol-3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fresno Vara JA, Casado E, De Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
|
|
12
|
Samuels Y, Wang ZH, Bardelli A, Silliman
N, Ptak J, Szabo S, Yan H, Gazdar A, Powell DM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bachman KE, Argani P, Samuels Y, Silliman
N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al:
The PIK3CA gene is mutated with high frequency in human breast
cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JW, Soung YH, Kim SY, Lee HW, Park WS,
Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: PIK3CA gene is
frequently mutated in breast carcinomas and hepatocellular
carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bader AG, Kang S, Zhao L and Vogt PK:
Oncogenic PI3K deregulates transcription and translation. Nat Rev
Cancer. 5:921–929. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang CH, Mandelker D, Gabelli SB and
Amzel LM: Insights into the oncogenic effects of PIK3CA mutations
from the structure of p110alpha/p85alpha. Cell Cycle. 7:1151–1156.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maekawa T, Ashihara E and Kimura S: The
Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents
against Philadelphia chromosome-positive leukemias. Int J Clin
Oncol. 12:327–340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA,
et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Ignat A and Axiotis CA:
Differential expression of the PTEN tumor suppressor protein in
fetal and adult neuroendocrine tissues and tumors: progressive loss
of PTEN expression in poorly differentiated neuroendocrine
neoplasms. Appl Immunohistochem Mol Morphol. 10:139–146. 2002.
View Article : Google Scholar
|
|
23
|
Yao JC: Neuroendocrine tumors. Molecular
targeted therapy for carcinoid and islet-cell carcinoma. Best Pract
Res Clin Endocrinol Metab. 21:163–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Righi L, Volante M, Rapa I, Tavaglione V,
Inzani F, Pelosi G and Papotti M: Mammalian target of rapamycin
signalling activation patterns in neuroendocrine tumors of the
lung. Endocr Relat Cancer. 17:977–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alì G, Boldrini L, Capodanno A,
Pelliccioni S, Servadio A, Crisman G, Picchi A, Davini F, Mussi A
and Fontanini G: Expression of p-AKT and p-mTOR in a large series
of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2:787–792.
2011.PubMed/NCBI
|
|
26
|
Campbell IG, Russell SE, Choong DYH,
Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB
and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast
cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li VSW, Wong CW, Chan TL, Chan ASW, Zhao
W, Chu KM, So S, Chen X, Yuen ST and Leung SY: Mutations of PIK3CA
in gastric adenocarcinoma. BMC Cancer. 5:292005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shibata T, Kokubu A, Tsuta K and Hirohashi
S: Oncogenic mutation of PIK3CA in small cell lung carcinoma: a
potential therapeutic target pathway for chemotherapy-resistant
lung cancer. Cancer Lett. 283:203–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Farina Sarasqueta A, Zeestraten EC, van
Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, Kuppen PJ,
Goossens-Beumer IJ, Lemmens VE, van de Velde CJ, et al: PIK3CA
kinase domain mutation identifies a subgroup of stage III colon
cancer patients with poor prognosis. Cell Oncol. 34:523–531.
2011.PubMed/NCBI
|
|
30
|
Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J,
Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, et al:
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and
response to neoadjuvant endocrine therapy for estrogen receptor
positive breast cancer. Breast Cancer Res Treat. 119:379–390. 2010.
View Article : Google Scholar
|
|
31
|
Miled N, Yan Y, Hon WC, Perisic O,
Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM
and Williams RL: Mechanism of two classes of cancer mutations in
the phosphoinositide 3-kinase catalytic subunit. Science.
317:239–242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rossi G, Cavazza A, Marchioni A, Longo L,
Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U,
et al: Role of chemotherapy and the receptor tyrosine kinases KIT,
PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine
carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Varlotto JM, Medford-Davis LN, Recht A,
Flickinger JC, Schaefer E, Zander DS and DeCamp MM: Should large
cell neuroendocrine lung carcinoma be classified and treated as a
small-cell lung cancer or with other large cell carcinomas? J
Thorac Oncol. 6:1050–1058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rossi G, Cavazza A, Marchioni A, Migaldi
M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S and
Crinò L: Kit expression in small cell carcinomas of the lung:
effects of chemotherapy. Mod Pathol. 16:1041–1047. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gustin JP, Cosgrove DP and Park BH: The
PIK3CA gene as a mutated target for cancer therapy. Curr Cancer
Drug Targets. 8:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pitt SC, Chen H and Kunnimalaiyaan M:
Phosphatidylinositol 3-kinase-Akt signalling in pulmonary carcinoid
cells. J Am Coll Surg. 209:82–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
